EMBLA narrows full-year organic growth outlook to about 5% on Patient Care
EMBLA posted nine-month sales of $741 million with 5% organic growth and narrowed its full-year guidance because of a slower Patient Care recovery.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, EMBLA posted nine-month sales of $741 million, with organic growth of 5%. The EBITDA margin in the third quarter held at 22%.
The company narrowed its full-year organic growth outlook to about 5%. The reason is a slower-than-expected recovery in Patient Care. Management expects a new Swedish tender to support growth in 2027.
why it matters
Narrowing the outlook to about 5% shows that recovery in a key business line is taking longer than planned, though a steady 22% margin provides a cushion. For investors, the Swedish tender and its effect on revenue in 2027 will be the next thing to watch.
market impact
EMBLA Medical: weaker Patient Care momentum puts moderate pressure on the company's shares
tags
instruments
sources
- EMBLA: Patient Care weakness narrowed FY organic growth guidance to around 5% — TradingView, 20 October 2026 at 08:47 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗